Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab

Fujita, R; Aratake, Y; Nakata, K; Fujii, C; Kondo, T

Fujii, C (通讯作者)，Kansai Med Univ, Dept Neurol, Med Ctr, Moriguchi, Japan.

INTERNAL MEDICINE, 2023; 62 (22): 3317

Abstract

Objective The interleukin-6 (IL-6) inhibitor satralizumab is an established treatment for neuromyelitis optica spectrum disorder (NMOSD). Although IL-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索